Compugen Goes the Extra Mile in Drug Discovery
Prohost Biotech submits:
With the evolution of the genomic and proteomic technologies, we highly regard and appreciate the firms that have invested in these technology towards breakthrough discoveries that are used in a therapeutic progress towards healing chronic and deadly diseases. One of these firms has offered us more than hints about what it can accomplish through its thoroughly developed technologies. The firm in question is Compugen (CGEN) and is still small as measured by its market cap, but we see it as a future giant based on its achievements. Using its LEADS Platform and other proprietary algorithms and technologies, Compugen was capable of predicting in silico the existence of novel members of the B7/CD28 family of co-stimulatory proteins, and discovering an extracellular region of the predicted (previously unknown) membrane protein in the B7/CD28 family.
B7/CD28 co-stimulation protein family is of extreme importance in immune regulation. Compugen’s predictive capability and experimental validation of a previously unknown member of this important protein family represents a major advancement in therapeutic discovery from being totally based on experimentation to originating from in silico prediction and selection new capabilities. With the discovery of the new extracelluar region membrane protein in the B7/CD28 family, Compugen has walked extra steps towards developing a product, CGEN-15001, as a novel soluble recombinant fusion protein that corresponds to the extracellular region of the discovered parent protein. Compugen is patenting both the parent protein, which potentially has other medical uses such as a target for antibody therapeutics, and its CGEN-15001 molecules.
Complete Story »
View full post on Seeking Alpha Small Cap stocks
